These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32854260)

  • 1. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.
    Albiñana V; Gallardo-Vara E; de Rojas-P I; Recio-Poveda L; Aguado T; Canto-Cano A; Aguirre DT; Serra MM; González-Peramato P; Martínez-Piñeiro L; Cuesta AM; Botella LM
    J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32854260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.
    Cuesta AM; Albiñana V; Gallardo-Vara E; Recio-Poveda L; de Rojas-P I; de Las Heras KVG; Aguirre DT; Botella LM
    Sci Rep; 2019 Jul; 9(1):10062. PubMed ID: 31296894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease.
    Shepard MJ; Bugarini A; Edwards NA; Lu J; Zhang Q; Wu T; Zhuang Z; Chittiboina P
    J Neurosurg; 2019 Oct; 131(4):1106-1114. PubMed ID: 30497198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
    Albiñana V; Villar Gómez de Las Heras K; Serrano-Heras G; Segura T; Perona-Moratalla AB; Mota-Pérez M; de Campos JM; Botella LM
    Orphanet J Rare Dis; 2015 Sep; 10():118. PubMed ID: 26394686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
    Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
    Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein.
    Wohlrab C; Vissers MCM; Phillips E; Morrin H; Robinson BA; Dachs GU
    Front Oncol; 2018; 8():574. PubMed ID: 30555801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
    Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
    Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.
    Liang X; Shen D; Huang Y; Yin C; Bojanowski CM; Zhuang Z; Chan CC
    Ophthalmology; 2007 Jan; 114(1):147-56. PubMed ID: 17070589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma.
    Schuhmacher P; Kim E; Hahn F; Sekula P; Jilg CA; Leiber C; Neumann HP; Schultze-Seemann W; Walz G; Zschiedrich S
    Orphanet J Rare Dis; 2019 Oct; 14(1):235. PubMed ID: 31661010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
    Zhou J; Li NY; Zhou XJ; Zhou HB; Wu B; Jiang SJ; Ma HH; Zhang RS
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):145-50. PubMed ID: 20450758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
    Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
    Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
    Cinque A; Minnei R; Floris M; Trevisani F
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.